The mainstay of therapy for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) is Alexion's infusion therapy Soliris, but Novartis' iptacopan could provide an oral option after ...
This first-in-class, oral Factor D inhibitor can now be used as an add-on to ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (PNH) in adults with residual haemolytic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback